ABSTRACT
ABSTRACT Objectives: This study aims to verify the new-onset diabetes after kidney transplant (NODAT) incidence in recipients within 1 year after kidney transplantation from a single center in Southern Brazil and to assess the associated conditions. Subjects and methods: A retrospective study of 258 post-renal transplant patients was performed. Demographic (gender, age, ethnic background) and clinical (origin of graft, associated infections, body mass index (BMI) at transplant time and 6 and 12 months after, causes of renal failure, and comorbidities) data were analyzed. All patients were on tacrolimus, mycophenolate mofetil, and prednisone treatment. Patients with and without NODAT were compared. Results: A NODAT incidence of 31.2% was noted 1 year post transplantation. In the univariate analysis, patients with NODAT were older (p = 0.001), mostly had African-American ethnic background (p = 0.02), and had renal failure secondary to high blood pressure (HBP) (p = 0.001). The group of patients with NODAT also had more incidence of post-transplant HBP (p = 0.01), heart failure (p = 0.02), and dyslipidemia (p = 0.001). Logistic regression showed that African-American ethnic background, post-transplant HBP, and dyslipidemia were independently associated with NODAT. Conclusion: This study shows a NODAT incidence that is greater in patients with African-American ethnic background and that is associated with HBP and dyslipidemia.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Postoperative Complications/etiology , Kidney Transplantation/adverse effects , Diabetes Mellitus/etiology , Postoperative Complications/epidemiology , Brazil/epidemiology , Logistic Models , Incidence , Retrospective Studies , Risk Factors , Tacrolimus/adverse effects , Statistics, Nonparametric , Diabetes Mellitus/epidemiology , Dyslipidemias/etiology , Hypertension/etiology , Immunosuppressive Agents/adverse effectsABSTRACT
New onset diabetes after transplantation is one of the most common metabolic complications following organ transplantation and closely correlates with the post transplant onsets of cardiovascular diseases, chronic graft loss, severe infection, decreasing long-term survival rate etc. The incidences of new onset diabetes following different organ transplantations vary greatly, so as the risk factors. In this review, the different incidences and risk factors following kidney, liver, heart, and lung transplantations are reviewed and summarized.
ABSTRACT
New onset diabetes after transplantation is one of the most common metabolic complications following organ transplantation and closely correlates with the post transplant onsets of cardiovascular diseases, chronic graft loss, severe infection, decreasing long-term survival rate etc. The incidences of new onset diabetes following different organ transplantations vary greatly, so as the risk factors. In this review, the different incidences and risk factors following kidney, liver, heart, and lung transplantations are reviewed and summarized.
ABSTRACT
BACKGROUND/AIMS: Metformin (MET) is a first-line drug for type 2 diabetes mellitus (DM); its effect on new-onset diabetes after transplantation caused by immunosuppressant therapy is unclear. We compared the effects of MET on DM caused by tacrolimus (TAC) or sirolimus (SRL). METHODS: DM was induced by injection of TAC (1.5 mg/kg) or SRL (0.3 mg/kg) for 2 weeks in rats, and MET (200 mg/kg) was injected for 2 more weeks. The effects of MET on DM caused by TAC or SRL were evaluated using an intraperitoneal glucose tolerance test (IPGTT) and by measuring plasma insulin concentration, islet size, and glucose-stimulated insulin secretion (GSIS). The effects of MET on the expression of adenosine monophosphate-activated protein kinase (AMPK), a pharmacological target of MET, were compared between TAC- and SRL-treated islets. RESULTS: IPGTT showed that both TAC and SRL induced hyperglycemia and reduced plasma insulin concentration compared with vehicle. These changes were reversed by addition of MET to SRL but not to TAC. Pancreatic islet cell size was decreased by TAC but not by SRL, but addition of MET did not affect pancreatic islet cell size in either group. MET significantly increased GSIS in SRL- but not in TAC-treated rats. AMPK expression was not affected by TAC but was significantly decreased in SRL-treated islets. Addition of MET restored AMPK expression in SRL-treated islets but not in TAC-treated islets. CONCLUSIONS: MET has different effects on hyperglycemia caused by TAC and SRL. The discrepancy between these drugs is related to their different mechanisms causing DM.
Subject(s)
Animals , Rats , Adenosine , AMP-Activated Protein Kinases , Cell Size , Diabetes Mellitus, Type 2 , Glucose Tolerance Test , Hyperglycemia , Insulin , Islets of Langerhans , Metformin , Models, Theoretical , Plasma , Protein Kinases , Sirolimus , TacrolimusABSTRACT
Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and graft survival rates. Thus, reducing the impact of NODAT could improve overall transplant success. The pathogenesis of NODAT is multifactorial, and both modifiable and nonmodifiable risk factors have been implicated. Monitoring and controlling the blood glucose profile, implementing multidisciplinary care, performing lifestyle modifications, using a modified immunosuppressive regimen, administering anti-metabolite agents, and taking a conventional antidiabetic approach may diminish the incidence of NODAT. In addition to these preventive strategies, inhibition of dipeptidyl peptidase-4 (DPP4) by the gliptin family of drugs has recently gained considerable interest as therapy for type 2 diabetes mellitus and NODAT. This review focuses on the role of DPP4 inhibitors and discusses recent literature regarding management of NODAT.